Though seldom previous research explored the clinical implications of concomitant mutations from multiple pathways in HER2-related signaling network for breast cancer, several previous studies [21–25] in EGFR-mutant advanced non-small cell lung cancer investigated the relationship between concomitant genetic alterations and survival outcomes. The gene discussed is EGFR; the disease is breast carcinoma.